2026-07-21T07:23:03Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231132024-11-29T15:14:00Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Zhou, Xiang author Han, Seungbin author Cebulla, Nadine author Haertle, Larissa author Steinhardt, Maximilian J author Schirmer, Daniel author Runau, Eva author Flamm, Leon author Terhorst, Calvin author Jähnel, Laura author Vogt, Cornelia author Nerreter, Silvia author Teufel, Eva author Stanojkovska, Emilia author Mersi, Julia author Munawar, Umair author Schindehütte, Magnus author Blum, Robert author Reinhold, Ann-Kristin author Scherf-Clavel, Oliver author Rittner, Heike L author Pham, Mirko author Rasche, Leo author Einsele, Hermann author Sommer, Claudia author Kortüm, K Martin author 2023-05-16 We analyzed single nucleotide polymorphisms (SNPs) in PKNOX1 (rs2839629) and in the intergenic region between PKNOX1 and CBS (rs915854) by Sanger sequencing in 88 patients with multiple myeloma treated with bortezomib. All patients (n = 13) harboring a homozygous mutation in PKNOX1 (rs2839629) also had a homozygous mutated rs915854 genotype. Homozygous mutated genotypes of rs2839629 and rs915854 were significantly enriched in patients with painful peripheral neuropathy (PNP) (P < 0.0001), and homozygous mutated rs2839629 genotype was significantly enriched in patients with pain compared to patients with no pain (P = 0.04). In summary, both SNPs rs2839629 and/or rs915854 may be potential biomarkers predicting an increased risk to develop painful PNP under bortezomib. Biomark Res . 2023 1;11(1):52 10.1186/s40364-023-00490-9 2050-7771 Biomarker research 37194045 https://hdl.handle.net/20.500.12105/23113 Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1